Measurement of Osteoarthritic Patient Pain Through Electrodermal Activity Signals

Who can take part

• Kellgren-Lawrence Grade >= 3

Who cannot take part

• Prior history of knee surgery, knee injections, or injury to knee joints (e.g., meniscus tears, ligamentous injuries), BMI >=35; Both groups, exclusion:
• Subjects with chronic heart problems, including, but not limited to, chronic hypertension, heart palpitations, a weak or irregular heartbeat, or a previous heart attack,
• Subjects taking the following drugs within 12 hours of the experiment or during the experiment: caffeine, alcohol, psychoactive drugs, nicotine or marijuana, other recreational drugs, and medicine of any kind that is not normally taken daily. Such medications include; NSAIDs; Acetaminophen; Steroidal anti-inflammatory agents; Bronchodilators; Appetite suppressants; Lipase inhibitors
• Subjects with Raynaud's syndrome
• Subjects with any of the following conditions: active skin lesions where EDA sensors are, vertigo or dizziness, and anyone with postural orthostatic tachycardia syndrome (POTS), peripheral neuropathy, seizure disorders, methicillin-resistant staphylococcus aureus (MRSA), impaired circulation, medical implants, open skin lesions, chronic eczema on hands where EDA and electrical stimulator's electrodes are attached, diabetes, and epilepsy
• Participants who cannot feel physical pain or have a history of self-harm
• Inflammatory arthropathy (e.g., rheumatoid arthritis), BMI >=35; Control subjects:
• Complaints of lower extremity joint pain
• Known diagnosis of knee osteoarthpathy
• Women who are currently pregnant
• Participants who have a skin sensitivity to metals, have a pacemaker or defibrillator, or have recent head trauma within the past two weeks (even without loss of consciousness)

Other criteria

• Study subjects